Genotypic sensitivity score of antiretroviral therapies in naïve HIV-1 infected pregnant women
Abstract
Background: The genotypic sensitivity score (GSS) is a tool to predict virological treatment outcome. The objective of this study is to compare the GSS of three antiretroviral treatment (ART) strategies in a population of naive pregnant women (NPW) in Buenos Aires city, Argentina.
Methods: Resistance tests from 47 NPW were analyzed in the context of a sentinel resistance surveillance study in Buenos Aires city (period 2008-2011), considering the genotype interpretation system of the Stanford HIVdb program (prevalence of primary drug resistance of 21.2%). The predicted efficacy of each drug was scored either as 1.00-0.75-0.50-0.25 and 0.00 for the five HIVdb categories: from susceptible to high-level resistance. GSS was obtained with the sum of the scores for the individual drugs included in a regimen (GSS of 3 means three fully active drugs). GSS of three ARTs were compared: zidovudine+lamivudine plus either nevirapine (ART1), nelfinavir (ART2) or lopinavir/ritonavir (ART3).
Results: A GSS of 3 was achieved in 80.9% with ART1 and 91.5% with both ART2 and ART3. There was no statistical difference in the possibility of achieving a GSS of 3 between the three ARTs evaluated.
Conclusions: There was no statistical difference in the probability of providing a fully active regimen with either a protease inhibitor or nevirapine. In our opinion, an ART with a high genetic barrier backbone may be preferred in the context of the high prevalence of primary resistance observed.
Downloads
Copyright (c) 2023 Diego Cecchini, Inés Zapiola, Silvia Fernández-Giuliano, María G. Martínez, Claudia G. Rodríguez, María B. Bouzas
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
When an article is finally accepted in the journal, its authors assign their economic rights on a non-exclusive basis in favor of the editors, who allow reuse under an “Attribution-NonCommercial-ShareAlike 4.0 International” License (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es). This implies that the articles can be shared (copy and redistribute the material in any medium or format) and adapted (remix, transform and create another work from the material), as long as the authorship and the original source of publication (journal, publisher and URL of the work) are cited, they are not used for commercial purposes, and the same terms of the license are respected. It is requested to cite the original source of publication.
In addition, the acceptance of the article by the journal implies on the part of the authors the non-submission of the material to other journals or editorial bodies.
